Search results
Is It Too Late to Buy Novavax Stock?
The Motley Fool via AOL· 2 days agoNovavax (NASDAQ: NVAX) stock is suddenly a buy again this year, with its stock price more than tripling since the start of 2024. Some positive developments in recent months ...
FDA advises Covid vaccine makers to target new contagious strain for fall shots
NBC Universal via AOL· 3 days agoThe FDA advised drugmakers to update Covid vaccines to target the KP.2 strain, a descendant of the...
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
The Motley Fool via AOL· 5 days agoYou'll find plenty of these stocks in the area of biotech and pharma -- let's check out three in...
COVID vaccine companies told to focus on KP.2 variant for fall shots, per FDA announcement
Fox News via Yahoo News· 1 day agoThe U.S. Food and Drug Administration (FDA) has recommended that COVID vaccine manufacturers update...
FDA asks COVID vaccine makers to target KP.2 strain, if feasible, for next shot
Reuters via Yahoo News· 2 days agoThe Food and Drug Administration's change in recommendation, in an update dated Thursday, comes even...
Abbott Labs Enters The U.S. Obesity Arena
Investor's Business Daily· 6 days agoAbbott Laboratories (ABT) gained U.S. clearance Monday for a pair of new continuous glucose monitors. The Food and Drug Administration signed off on...
FDA modifies strain recommendation for fall COVID vaccine amid variant shifts, uptick in cases
Center for Infectious Disease Research and Policy· 2 days agoOn June 5, the FDA's vaccine advisory group recommended a switch to the JN.1 variant, though it held...
Bull Market and Beyond: 3 Stocks Just Waiting to Soar | The Motley Fool
The Motley Fool· 5 days agoThe S&P 500 rose to a record high earlier this year, confirming its presence in a bull market, and...
KP.3 is the dominant COVID-19 variant in the US: Latest on test positivity, deaths, symptoms
USA Today· 3 days agoCases of the latest COVID-19 variant, also known as KP.3, are on the rise in the United States....
Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review
Zacks via Yahoo Finance· 6 days agoModerna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19...
